Jazz Pharmaceuticals plc
Dublin, North Rhine-Westphalia, United States · Biopharma, Biotechnology, Health Care
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. The company's diverse portfolio of transformative medicines extends across the areas of neuroscience, sleep, hematology/oncology, and other therapeutic areas.
Key facts
- Headquarters
- Dublin, North Rhine-Westphalia, United States
- Employees
- 3,430
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (JAZZ)
- Website
- jazzpharmaceuticals.com.au
- Company page
Recent activity at Jazz Pharmaceuticals plc
- : SEC 8-K (1.01): On September 23, 2026, Jazz Pharmaceuticals plc, through its subsidiary Jazz Financing Lux S.à r.l., entered into Amendment No. 4 to the existing Credit Agreement dated May 5, 2021. This amendment is aimed at extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility initially incurred on July 19, 2024. Key parties involved include Jazz Lux as the borrower and Bank of America, N.A. serving as the administrative agent. The strategic implications of this amendment are significant as it potentially lowers borrowing costs and provides greater financial flexibility for the company.
- : SEC 8-K (2.01): Jazz Pharmaceuticals plc announced the completion of its acquisition of Actio Biosciences, Inc. on September 15, 2026. Following the acquisition, Actio has become a wholly-owned subsidiary of Jazz Pharmaceuticals. This acquisition marks a strategic expansion for Jazz, potentially enhancing its research and development capabilities. The financial specifics regarding the acquisition amount or terms were not detailed in the announcement. The deal was confirmed through a press release attached as Exhibit 99.1.
- : Jazz Pharmaceuticals acquires Actio Biosciences
- : Jazz Pharmaceuticals and AbCellera Collaborate for Development of Next-Generation T-cell Engaging Antibodies.
- : SEC 8-K (5.02): On May 25, 2026, Anne O’Riordan, a Class III director of Jazz Pharmaceuticals plc, announced she will not seek re-election at the upcoming 2026 annual meeting of shareholders. This decision aligns with the company's strategy for ongoing board refreshment and effectiveness. Importantly, her choice was not due to any disagreements or disputes regarding the company's operations or policies. The board will continue to review its composition to ensure effective succession planning.
- : Jazz Pharmaceuticals Partners with Boehringer Ingelheim for HER2 Cancer Treatment and Sells FDA Voucher for $200 Million.
- : SEC 8-K (8.01): On November 17, 2025, Jazz Pharmaceuticals plc announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial for Ziihera (zanidatamab-hrii), which is being evaluated as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, in combination with chemotherapy and with or without the checkpoint inhibitor tislelizumab. These trial results signify potential advancements in oncology treatment and reflect Jazz Pharmaceuticals' commitment to developing innovative therapies for cancer patients. The announcement may have significant implications on the company's strategic direction and market position in oncology therapeutics.
- : SEC 8-K (5.02): On October 23, 2025, Jazz Pharmaceuticals plc appointed Dr. Ted Love to its Board of Directors, effective December 1, 2025. He has been designated as a Class I director with a term expiring at the annual general meeting of shareholders in 2027. Additionally, Dr. Love will serve on both the Audit Committee and the Science and Medicine Committee of the Board. He will receive cash and equity compensation aligned with the company's standard practices. The appointment indicates a strategic move to enhance the Board's expertise in medicine and governance, reflecting the company's commitment to strong leadership.
- : Jazz Pharmaceuticals Appoints Renee Gala as Chief Executive Officer
- : $634 thousand Award for Jazz Pharmaceuticals, Inc
Leadership
- Renee Gala, President
- Sam Pearce, Chief Commercial Officer
- Philip Johnson, Chief Financial Officer
Verified email and direct lines for Jazz Pharmaceuticals plc’s decision-makers are on Fundz. See plans
Employee benefit plans
Jazz Pharmaceuticals plc files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Jazz Pharmaceuticals plc in the news
- Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PR Newswire (Apr 09, 2026)
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma - Jazz Pharmaceuticals (Jun 30, 2021)
- Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma - PR Newswire (Sep 21, 2023)
- Cannabis Pharmaceuticals Market Size Report, 2024-2030 - Grand View Research (May 26, 2020)
- Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting - PR Newswire (Dec 05, 2025)
Companies similar to Jazz Pharmaceuticals plc
- Innovent Biologics (Innovent) · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- MacroGenics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Jazz Pharmaceuticals plc: questions and answers
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. The company's diverse portfolio of transformative medicines extends across the areas of neuroscience, sleep, hematology/oncology, and other therapeutic areas.
Where is Jazz Pharmaceuticals plc headquartered?
Jazz Pharmaceuticals plc is headquartered in Dublin, North Rhine-Westphalia, United States.
How many employees does Jazz Pharmaceuticals plc have?
Jazz Pharmaceuticals plc has about 3,430 employees.
Who leads Jazz Pharmaceuticals plc?
Renee Gala is a President at Jazz Pharmaceuticals plc.
What is the latest news on Jazz Pharmaceuticals plc?
On Sep 23, 2026, SEC 8-K (1.01): On September 23, 2026, Jazz Pharmaceuticals plc, through its subsidiary Jazz Financing Lux S.à r.l., entered into Amendment No. 4 to the existing Credit Agreement dated May 5, 2021. This amendment is aimed at extending the maturity date and repricing the outstanding U.S. dollar term
Is Jazz Pharmaceuticals plc a public company?
Yes. Jazz Pharmaceuticals plc is publicly traded under the ticker JAZZ.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy